Early data suggest Roche's NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A
Positive phase I/II data presented at the 2025 International Society on Thrombosis and Haemostasis (ISTH) Congress show NXT007 achieved no bleeds requiring treatment in the highest dose groups in people with haemophilia A1
The NXT007 clinical development programme aims to normalise haemostasis and minimise treatment burden2,3
Three phase III clinical studies on NXT007, a next-generation bispecific antibody, set to begin in 20261
Basel, 23 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive phase I/II data on NXT007 in people with haemophilia A, supporting its progression into phase III clinical development. NXT007 is a next-generation investigational bispecific antibody, engineered by Chugai, a member of the Roche Group. Early data from the NXTAGE study suggest that NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A (without factor VIII inhibitors). NXT007 showed a tolerable safety profile with no thromboembolic events reported so far.1 These results were featured as an oral presentation at the 2025 International Society on Thrombosis and Haemostasis (ISTH) Congress, 21-25 June, Washington D.C., United States.1
'These NXT007 data are promising for people with haemophilia A and underscore our ongoing commitment to advancing care and addressing the real-world challenges faced by this community,' said Levi Garraway, MD, PhD, Roche's Chief Medical Officer and Head of Global Product Development. 'Hemlibra established a new standard of care, and our focus is to continue to deliver breakthrough innovation that might ultimately help people with haemophilia to live their lives in a manner unaffected by this condition.'
NXT007 leverages the Roche Group's expertise in haemophilia A and bispecific antibody development. Our goal is to bring a next generation prophylactic to our portfolio, offering greater therapeutic choice, sustained, elevated bleed protection and reduced treatment burden with factor independence - to allow patients to experience freedom from constant vigilance and have confidence in bleed protection.
NXT007 will be further evaluated in a robust clinical development programme, including ongoing phase I/II clinical trials, with additional phase II data expected later this year. There are also three phase III studies currently planned for 2026, including a phase III head-to-head study with Roche's Hemlibra, the first available prophylactic treatment that can be administered subcutaneously and with flexible dosing options (every week, two weeks or four weeks).4,5
Part B of the phase I/II NXTAGE study, conducted by Chugai, in Japan, Taiwan and South Korea, is evaluating the safety, pharmacokinetics, pharmacodynamics and efficacy of prophylaxis with NXT007 in people with haemophilia A without factor VIII inhibitors who had not been previously treated with Hemlibra® (emicizumab).1 Thirty participants (from 12 to 65 years of age) were enrolled in four cohorts (B-1 to B-4) to receive ascending doses of subcutaneous NXT007 every two-to-four weeks during the maintenance period (following four-to-six weeks of loading doses). In presented data from the primary analysis, no treated bleeds were observed with NXT007 in the highest dose cohorts (B-3 and B-4). NXT007 was well tolerated, with no thromboembolic events observed so far.1
About NXT007NXT007 is a next-generation investigational bispecific antibody, being investigated as a prophylactic (preventive) treatment option for people with haemophilia A.1,2,3
NXT007 was engineered by Chugai – a member of the Roche Group – built on Hemlibra® (emicizumab)'s framework, with the aim of optimising factor VIII-mimetic activity and half-life, to further enhance potency, efficacy, dosing and administration convenience. NXT007 brings together factor IXa and factor X, proteins required to activate the natural coagulation cascade.1,2,3 NXT007 is being studied in a robust clinical development programme exploring its potential to achieve sustained elevated bleed protection equivalent to people who do not have haemophilia A (sustained haemostatic normalisation), and reduced treatment burden with factor independence, offering people living with haemophilia A greater therapeutic choice.1,2,3
About haemophilia AHaemophilia A is an inherited, serious disorder in which a person's blood does not clot properly, leading to uncontrolled and often spontaneous bleeding. Haemophilia A affects around 900,000 people worldwide.6,7 People with haemophilia A either lack or do not have enough of a clotting protein called factor VIII. In a healthy person, when a bleed occurs, factor VIII brings together the clotting factors IXa- and X, which is a critical step in the formation of a blood clot to help stop bleeding. Depending on the severity of their symptoms, people with haemophilia A can bleed frequently, especially into their joints or muscles.8 These bleeds can present a significant health concern as they often cause pain and can lead to chronic swelling, deformity, reduced mobility and long-term joint damage.9 A serious complication of treatment is the development of inhibitors to factor VIII replacement therapies. Inhibitors are antibodies developed by the body's immune system that bind to and block the efficacy of replacement factor VIII, making it difficult, if not impossible, to obtain a level of factor VIII sufficient to control bleeding.6
About Roche in haematologyRoche has been developing medicines for people with malignant and non-malignant blood diseases for more than 25 years; our experience and knowledge in this therapeutic area runs deep. Today, we are investing more than ever in our effort to bring innovative treatment options to patients across a wide range of haematologic diseases. Our approved medicines include MabThera®/Rituxan® (rituximab), Gazyva®/Gazyvaro® (obinutuzumab), Polivy® (polatuzumab vedotin), Venclexta®/Venclyxto® (venetoclax) in collaboration with AbbVie, Hemlibra® (emicizumab), PiaSky® (crovalimab), Lunsumio® (mosunetuzumab) and Columvi® (glofitamab). Our pipeline of investigational haematology medicines includes T-cell engaging bispecific antibody cevostamab, targeting both FcRH5 and CD3 and Tecentriq® (atezolizumab). Our scientific expertise, combined with the breadth of our portfolio and pipeline, also provides a unique opportunity to develop combination regimens that aim to improve the lives of patients even further.
About Roche Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
For over 125 years, sustainability has been an integral part of Roche's business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
References[1] 1. Shima M, et al. NXT007 Prophylaxis in Emicizumab-Naive Persons with Hemophilia A without Inhibitor: Phase I/II Study (NXTAGE) Presented at International Society on Thrombosis and Haemostasis (ISTH) congress; 2025 June. Abstract OC.20.3.[2] Shima M, et al. Safety, Pharmacokinetics, and Pharmacodynamics of Single Subcutaneous Injection of NXT007, an Emicizumab-Based Next-Generation Bispecific Antibody, in Healthy Volunteers (NXTAGE Study). Presented at: International Society on Thrombosis and Haemostasis (ISTH) Congress; 2023 July 28. Abstract OC 69.4. [3] Teranishi-Ikawa Y., et al. A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a non-hemophiliac state. Journal of Thrombosis and Haemostasis. 2023; doi: 10.1016/j.jtha.2023.09.034[4] Hemlibra SmPC [Internet; cited 2025 June] Available from: https://www.medicines.org.uk/emc/product/9043/smpc [5] FDA Prescribing Information [Internet; cited 2025 June]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761083s002s004lbl.pdf. [6] Srivastava A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26 (Suppl 6): 1-158.[7] Iorio A, et al. Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males. Ann Intern Med. 2019;171(8):540-546.[8] NHS. Symptoms of haemophilia [Internet; cited 2025 June]. Available from: https://www.nhs.uk/conditions/haemophilia/symptoms/. [9] Franchini M, et al. Haemophilia A in the third millennium. Blood Rev. 2013; 179-84.
Roche Global Media RelationsPhone: +41 61 688 8888 / e-mail: media.relations@roche.com
Hans Trees, PhDPhone: +41 79 407 72 58
Sileia UrechPhone: +41 79 935 81 48
Nathalie AltermattPhone: +41 79 771 05 25
Lorena CorfasPhone: +41 79 568 24 95
Simon GoldsboroughPhone: +44 797 32 72 915
Karsten KleinePhone: +41 79 461 86 83
Nina MählitzPhone: +41 79 327 54 74
Kirti PandeyPhone: +49 172 6367262
Yvette PetillonPhone: +41 79 961 92 50
Dr Rebekka SchnellPhone: +41 79 205 27 03
Roche Investor Relations
Dr Bruno EschliPhone: +41 61 68-75284e-mail: bruno.eschli@roche.com
Dr Sabine BorngräberPhone: +41 61 68-88027e-mail: sabine.borngraeber@roche.com
Dr Birgit MasjostPhone: +41 61 68-84814e-mail: birgit.masjost@roche.com
Investor Relations North America
Loren KalmPhone: +1 650 225 3217e-mail: kalm.loren@gene.com
Attachment
Media Investor Release phase I_II data on NXT007 EnglishError al recuperar los datos
Inicia sesión para acceder a tu cartera de valores
Error al recuperar los datos
Error al recuperar los datos
Error al recuperar los datos
Error al recuperar los datos
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
38 minutes ago
- CNN
Health insurers promise to simplify care preapproval process
Months after the killing of a top health insurance executive unleashed Americans' pent-up anger over denials of medical care, the industry announced Monday that it will take action to 'streamline, simplify and reduce' the preapproval process. Dozens of health insurers, who cover 257 million people, committed to six steps to make it easier for patients to get appropriate care, according to a news release from the industry's two major trade groups, the Blue Cross Blue Shield Association and AHIP, formerly known as America's Health Insurance Plans. The measures apply to those with commercial, Medicare Advantage and Medicaid-managed care coverage. 'For patients, these commitments will result in faster, more direct access to appropriate treatments and medical services with fewer challenges navigating the health system,' the release said. 'For providers, these commitments will streamline prior authorization workflows, allowing for a more efficient and transparent process overall, while ensuring evidence-based care for their patients.' The announcement comes a little over six months after UnitedHealthcare CEO Brian Thompson was fatally shot in New York City, sparking a flurry of rage and frustration about care denials and delays from social media users. Luigi Mangione, who vented his anger with the health insurance industry in diary entries before Thompson's death, is facing charges in two states and federal court in connection with the killing. He has pleaded not guilty. The preapproval process, known as prior authorization, has long been a major headache for many patients. It's not uncommon for Americans and their doctors to go through multiple hoops to get approval for the care doctors say their patients need or to combat denials from carriers. The industry considers prior authorization an important safeguard to make sure their policyholders' care is safe, appropriate and affordable. But critics say it's a way for insurers to increase their profits by denying care. The participating health insurers have promised to work toward a common electronic prior authorization process, which they say will help speed the decision timeline. The goal is for the new framework to be in place by January 1, 2027. Also, the insurers have agreed to reduce the scope of claims subject to preapproval by the start of next year, as well as ensure that plans honor existing prior authorizations for 90 days for patients who change carriers during treatment. Insurers say they will provide clear explanations of their determinations, including information about appeals. These changes will be in place for those with commercial coverage by January, and the industry will work with regulators to expand this step to other coverage types. Plus, insurers will expand the share of electronic prior authorization approvals answered in real time to at least 80% in 2027, if all needed clinical documentation is submitted. And all requests that are denied will continue to be reviewed by medical professionals, which is the current standard. Insurers that have signed onto the commitment include many of the nation's largest carriers, including UnitedHealthcare, CVS Health's Aetna, Cigna, Humana, Elevance Health (formerly Anthem), Kaiser Permanente and dozens of Blue Cross Blue Shield plans. Several insurers have already promised to change their practices. UnitedHealthcare, for instance, said in January that it would work to use technology and standardization to speed up the preapproval process for Medicare Advantage patients and to reduce number of prior authorizations needed for certain Medicare Advantage services. The following month, Cigna said it would create concierge teams to help patients who are experiencing challenges with prior authorization or claims payments, as well as provide doctors with an easier way to submit all the needed info. US Health and Human Services Secretary Robert F. Kennedy Jr. and Dr. Mehmet Oz, Centers for Medicare and Medicaid Services administrator, are expected to discuss the initiative in a news conference on Monday, the Wall Street Journal reported late last week.
Yahoo
41 minutes ago
- Yahoo
Despite symptoms, menopausal women embrace youthful mindset
A surprising 43% of menopausal and post-menopausal women feel younger than they actually are, according to new research. The survey of 1,000 menopausal women and 1,000 post-menopausal women found that in spite of the aches, pains and emotional side effects of menopause, many are feeling more youthful than expected — and a lot of it has to do with a positive mindset and approach to life, according to the study. Conducted by Talker Research and commissioned by Solaray, the study uncovered some of the most unexpected menopausal symptoms, how this stage has influenced women's lives, relationships and self-image and how they've used it as an opportunity for getting in touch with their bodies. According to the study, the most unexpected menopausal symptoms for the women polled were hot flashes (40%), night sweats (34%), weight gain (28%), mood swings (23%), insomnia (21%) and joint and muscle aches (20%).
Yahoo
41 minutes ago
- Yahoo
Can Investing $10,000 in Quantum Computing (QUBT) Stock Turn Into $1 Million by 2035?
Quantum Computing would need to deliver a CAGR of roughly 58.49% to turn $10,000 into $1 million by 2035. Explosive growth in the photonic integrated circuit market could help the company achieve this goal. However, the probability that Quantum Computing will be a millionaire-maker in 10 years is still low. 10 stocks we like better than Quantum Computing › Quantum Computing (NASDAQ: QUBT) is an up-and-coming pioneer in the red-hot field of quantum computing. Could investing $10,000 in this stock turn into $1 million by 2035? It's possible, but the odds are stacked against it. That said, I think there is a viable path for Quantum Computing to make you a millionaire over the next 10 years. Here's what would be required. Quantum Computing's market cap currently hovers around $2.66 billion. Its share price was $18.88 at the market close on June 20, 2025. An investment of $10,000 would buy 529 shares at that price, with $12.48 left over. The company's share price would need to grow 100x to $1,888 for a $10,000 initial investment (assuming you didn't buy any fractional shares) to be worth $1 million in a decade. That reflects a compound annual growth rate (CAGR) of roughly 58.49%. Quantum Computing has certainly demonstrated that it can deliver a much greater annual return than that over the short term. Over the last 12 months, the stock has skyrocketed by more than 3,000%. Sustaining a CAGR of 58.49% over 10 years is a daunting task, but it's not impossible. For example, a $10,000 investment in Nvidia in 2015 would be worth over $2.6 million today. Of course, you would have had to resist the temptation to sell during the GPU stock's huge swings up and down during that period. Now for a more difficult question: How could Quantum Computing stock achieve a CAGR of 58.49% over the next 10 years? To answer this question, we need to understand the company's business. Quantum Computing uses integrated photonics (computing with particles of light) and nonlinear quantum optics to develop quantum computers. The company believes its approach to quantum computing is superior to rivals' methods that use superconducting, trapped-ion, and annealing architectures. Photons' advantages include lower energy consumption, faster processing, and scalability. The photonic integrated circuit market size in 2024 was around $15 billion. Over the next five years, this market is projected to expand by a CAGR of 20.5% to $38.4 billion. While that is an impressive growth rate, it isn't enough to propel Quantum Computing stock 100x higher. But Quantum Computing could grow significantly faster than the overall photonic integrated circuit market. The company's thin film lithium niobate wafers, which it believes will be "the silicon of the future," could make it possible. Also, the photonic integrated circuit market's growth could accelerate beyond 2029. I could envision this occurring if the adoption of the technology in areas such as artificial intelligence (AI), autonomous vehicles, and high-performance computing takes off in a huge way. It's quite possible that investing $10,000 in Quantum Computing stock could make you a millionaire over the next 10 years. But how probable is this scenario? The odds aren't great. For one thing, Quantum Computing's photonics technology might be surpassed by approaches that prove to be even better. Many of the companies investing heavily in developing quantum computers have deep pockets, including Google parent Alphabet, Amazon, IBM, Microsoft, and Nvidia. Other rising stars in the quantum computing industry, such as IonQ, D-Wave Quantum, and Rigetti Computing, could potentially be bigger winners than Quantum Computing. Perhaps progress in advancing quantum computing technology won't be fast enough to support the market growth required for Quantum Computing to be a millionaire-maker. I suspect that won't be the case, but I wouldn't rule it out. The good news for investors, though, is that Quantum Computing doesn't have to turn an initial $10,000 into $1 million by 2035 to still deliver exceptional returns. Before you buy stock in Quantum Computing, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Quantum Computing wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Keith Speights has positions in Alphabet, Amazon, and Microsoft. The Motley Fool has positions in and recommends Alphabet, Amazon, International Business Machines, Microsoft, and Nvidia. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Can Investing $10,000 in Quantum Computing (QUBT) Stock Turn Into $1 Million by 2035? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
